We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen (H1N1VAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01003288
Recruitment Status : Completed
First Posted : October 28, 2009
Results First Posted : August 24, 2016
Last Update Posted : November 7, 2016
Haukeland University Hospital
Information provided by (Responsible Party):
Rebecca Cox, University of Bergen

October 27, 2009
October 28, 2009
June 6, 2015
August 24, 2016
November 7, 2016
October 2009
January 2010   (Final data collection date for primary outcome measure)
Number of Participants With Local and Systemic Adverse Events [ Time Frame: 21 days after vaccination ]
Solicited adverse events were collected on side reactions form which were filled in for 21 days after pandemic or seasonal vaccination.
The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered adjuvanted H1N1 influenza vaccine in all volunteers [ Time Frame: 2010 ]
Complete list of historical versions of study NCT01003288 on ClinicalTrials.gov Archive Site
Number of Participants With Immunogenicity as Determined Using Haemagglutination Inhibition Assay [ Time Frame: 7, 14, 21 days post vaccination and long term follow up for 5 years ]
Antibody responses were measured using the HI assay to evaluate the rapidity and long term duration of the response
The secondary endpoints are the evaluation of the immunogenicity of adjuvanted H1N1 influenza vaccine and the ability of the vaccine to meet the CHMP evaluation criteria in a subset of volunteers [ Time Frame: 2011 ]
Not Provided
Not Provided
Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen
Safety and Immunogenicity Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen
Haukeland University Hospital has approximately 8000 employees many of whom will be in the front line to receive the pandemic A/H1N1 vaccine. We propose to conduct a safety and immunogenicity study in these subjects

The investigators will conduct a safety and immunogenicity study in health employees as detailed below:

  • Examine adverse events of all employees after vaccination using adverse events form
  • Examine the immunogenicity of the vaccine by collecting blood samples at days 0, 21 & 42 after vaccination (up to 500 people)
  • Provide a detailed time course of the immune response to vaccination with a novel influenza H1N1 virus including the kinetics of the T-cell, B-cell and antibody responses in 50 volunteers
  • Investigate the long lasting immunity induced by the vaccine
  • Examine the ability of the vaccine to induce cross-reactive immunity to H1N1 strains.
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Biological: Adjuvanted influenza H1N1split virion vaccine

Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)

* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)

Other Name: Pandemrix
Experimental: Pandemic influenza H1N1 vaccine
Influenza vaccine
Intervention: Biological: Adjuvanted influenza H1N1split virion vaccine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2014
January 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Signed informed consent Subjects able to understand and comply with the study protocol and complete the Adverse Event Form Subjects able to attend the scheduled visits for the kinetic study

Exclusion Criteria:

  • Persons with a history of anaphylaxis or serious reactions to any vaccine
  • Person with known hypersensitivity to any of the vaccine components
  • Persons who have had a temperature >38oC during the previous 72 hours
  • Persons who have had an acute respiratory infection during the last 7 days
  • Suspected non-compliance
Sexes Eligible for Study: All
19 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
H1N1VAC-2009, Version 1
2009-016456-43 ( EudraCT Number )
Not Provided
Not Provided
Rebecca Cox, University of Bergen
University of Bergen
Haukeland University Hospital
Study Chair: Per Espen Akselsen, MD Haukeland University Hospital
Study Chair: Haakon Sjursen, MD PhD Haukeland University Hospital
University of Bergen
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP